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Abstract
Background: Depression and elevated depression symptoms are more prevalent in patients with
type 2 diabetes than in those without diabetes and are associated with adverse health outcomes
and increased total healthcare utilization. This suggests that more effective depression treatment
might not only improve health outcome, but also reduce costs. However, there is a lack of evidence
on (cost-) effectiveness of treatment options for minor and mild-major depression in patients with
type 2 diabetes. In this paper we describe the design and methods of the economic evaluation,
which will be conducted alongside the MIND-DIA trial (Cognitive behaviour therapy in elderly type
2 diabetes patients with minor or mild-major depression). The objective of the economic
evaluation (MIND-DIA CEA) is to examine incremental cost-effectiveness of a diabetes specific
cognitive behaviour group therapy (CBT) as compared to intensified treatment as usual (TAU) and
to a guided self-help group intervention (SH).
Methods/Design: Patients will be followed for 15 months. During this period data on health
sector costs, patient costs and societal productivity/time costs will be collected in addition to
clinical data. Person-years free of moderate/severe major depression, quality adjusted life years
(QALYs), and cumulative costs will be estimated for each arm of the trial (CBT, TAU and SH). To
determine cost-effectiveness of the CBT, differences in costs and effects between the CBT group
and TAU/SH group will be calculated.
Discussion: CBT is a potentially effective treatment option to improve quality of life and to avoid
the onset of a moderate/severe major depression in elderly patients with type 2 diabetes and minor
or mild-major depression. This hypothesis will be evaluated in the MIND-DIA trial. Based on these
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results the associated economic evaluation will provide additional evidence on the cost-
effectiveness of CBT in this target population. Methodological strengths and weaknesses of the
planned economic evaluation are discussed.
Trial registration: The MIND-DIA study has been registered at the Current Controlled Trials
Register (ISRCTN58007098).
Background
Depression is a highly prevalent disorder with a substan-
tial impact on quality of life and societal cost [1,2]. This
applies in particular to patients with diabetes, since
depression has been shown to be more prevalent among
these patients as compared to those without diabetes [3-
5]. Major depression and elevated depression symptoms
were present, respectively, in 11 and 31% of individuals
with diabetes according to a meta-analysis [4]. Previous
research demonstrates that comorbid depression in
patients with diabetes is associated with poor self care, i.e.
adherence to medication, diet, exercise and smoking ces-
sation [6-8], additive functional impairment and work
disability [9], poorer glycaemic control [10], higher risk of
microvascular and macrovascular complications [11,12],
decreased quality of life [13], higher mortality [14,15],
increased healthcare utilization and higher costs for other
health conditions [7,16-19] as compared to patients with
diabetes only.
Hence, the more effective depression treatment might not
only improve health outcomes, but also reduce total
health service utilization and therefore costs. Put differ-
ently, additional costs for improved depression treatment
could be offset by reduction in other healthcare costs. For
example, among older adults with diabetes in the
IMPACT trial [20] systematic depression treatment had
significant clinical benefit with no increase in overall
healthcare costs.
Cost-effectiveness of antidepressive therapies has been
mainly evaluated for major depression co-occurring with
diabetes. However, since both major depression and
depressive symptoms are associated with adverse out-
comes in diabetes, there is a need to examine cost-effec-
tiveness of treatment options for minor and mild-major
depression as well, which is underscored by high preva-
lence of elevated depression symptoms in patients with
diabetes and growing prevalence of diabetes due to the
demographic change.
In what follows, we outline the economic evaluation of a
cognitive behaviour therapy for treatment of minor or
mild-major depression in elderly patients with type 2 dia-
betes that will be conducted alongside the MIND-DIA
trial. Full details on the design and methods of the MIND-
DIA trial will be provided elsewhere (Petrak et al, in prep-
aration). Here, after giving a brief overview of the MIND-
DIA trial, we focus on describing design and methods of
the associated economic evaluation (MIND-DIA CEA).
Methods/design
Overview of the MIND-DIA trial
MIND-DIA trial is a multicentre, open, observer-blinded,
randomized controlled trial, which will evaluate the effec-
tiveness of a diabetes-specific cognitive behaviour group
therapy (CBT) for treatment of a minor or mild-major
depression in subjects 65–85 years of age with type 2 dia-
betes comparing it to intensified treatment as usual (TAU)
or a guided self-help intervention "Successful aging with
Diabetes" (SH). Approval for conducting this study was
granted by the local Medical Ethics Committee (Ethik-
kommission bei der Landesärztekammer Hessen).
Study sample
A total number of 315 subjects will be included in the
study. Patients will be recruited in approximately 20 cen-
tres specialising on diabetes treatment in Germany. In the
participating centres all 65 to 85 year old patients with
type 2 diabetes, who give informed consent, will be
screened in a two-stage procedure (Patient Health Ques-
tionnaire (PHQ-9) [21] followed by the Structured Clini-
cal Interview for the DSM IV (SCID) [22]). All patients
with minor depression (adapted from the DSM-IV-TR
research criteria: 3–4 symptoms rather than 2–4 symp-
toms are required, and a past history of major depression
is not an exclusion criterion), or mild-major depression (5
to 6 depressive symptoms according to DSM-IV-TR crite-
ria) will be included in the trial, provided that they meet
other inclusion and exclusion criteria (inclusion of
patients with diabetes mellitus type 2 diagnosed at least 6
months before entering the trial, residence near the insti-
tution where intervention and control treatments will take
place (< 1 hour access); exclusion: e.g. history of schizo-
phrenia, psychotic symptoms, or dementia, current anti-
depressant or relevant psychoactive medication).
Interventions
Patients included in the MIND-DIA trial will be rand-
omized to one of the following interventions: CBT, SH or
TAU. CBT is a manual-based diabetes-specific cognitive
behaviour therapy, delivered by trained psychologists in
small groups in an outpatient setting. The guided self-help
group intervention 'Successful aging with Diabetes' (SH)BMC Geriatrics 2009, 9:25 http://www.biomedcentral.com/1471-2318/9/25
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with a focus on living and ageing with diabetes will be
delivered by trained moderators (elderly care nurses,
nurses or others). SH will include information regarding
diabetes and ageing shared by members of the group. This
intervention was conceptualized as a control condition
for unspecific group effects (e.g. cohesion). Hence, no for-
mal therapeutic aspects will be involved. In patients
assigned to intensified usual care (TAU), treating physi-
cians will be notified about the patient's minor or mild
depression symptoms and cognitive function. Further,
information on available therapeutic options will be pro-
vided to physicians. However, any treatment option may
be chosen (antidepressant medication, psychotherapeutic
interventions or no specific intervention), since care as
usual for a minor depression is currently not formalized.
For patients of the CBT and SH groups the trial will com-
prise two phases: (1) 12 weeks of open-label therapy
(weekly sessions of two hours each) and (2) one year
maintenance phase, during which both group interven-
tions (CBT and SH) will be reduced to one session per
month. Usual diabetes therapy is not a part of the proto-
col and will be delivered by the treating physicians 'as
usual'. For the first funding phase, the duration of the
MIND-DIA trial is expected to be approximately 36
months. Recruitment of patients started in May 2009.
Clinical outcomes
Primary clinical endpoint will be the improvement in
health-related quality of life (HRQoL) at one year follow-
up after the 12 weeks of therapy as measured by the Men-
tal Component Summary Score of the SF-36. Secondary
clinical endpoints are Physical Component Summary
score of the SF-36, improvement in HRQoL measured by
the EQ-5D; reduction of minor or mild-major depression
symptoms (QIDS-C-16); prevention of moderate/severe
major depression (Depression module, Structured Clini-
cal Interview for DSM-IV, SCID); improvement of glycae-
mic control (centrally measured HbA1c) and mortality.
Sample size calculation
The power calculation was based on expected differences
in SF-36 z-scores. Differences of δ = 0.6 between CBT and
TAU and of δ = 0.4 between CBT and SH were assumed.
For the latter comparison 132 patients per intervention
group were needed to detect a significant difference with
a power of 90% (2-sided t-test, α = 0.05). Given 132
patients in the CBT group it is sufficient to enroll 51
patients in the TAU group to achieve a power of 95% for
the comparison CBT vs. TAU. It is therefore planned to
recruit a total number of 315 patients (132 in CBT, 132 in
SH and 51 in TAU).
Economic evaluation alongside the MIND-DIA trial 
(MIND-DIA CEA)
Outline of the economic analysis
The economic evaluation will be performed alongside the
MIND-DIA clinical trial over the complete trial period.
Costs and effects will be discounted at the rate recom-
mended by the German guidance for economic evalua-
tion issued by the Institute for Quality and Efficiency in
the Health Care Sector (IQWiG), which is currently 3%.
The economic evaluation will be undertaken from the per-
spective of the German statutory health insurance and
from the societal perspective on costs. Accordingly, health
sector costs, patient costs and societal productivity/time
costs will be included in the analysis (Table 1).
The three outcomes estimated for the economic analysis
will be person-years free of moderate/severe major depres-
sion, quality adjusted life years (QALYs), and cumulative
cost accrued in each arm of the trial (CBT, TAU and SH).
To estimate cost-effectiveness of CBT, an incremental cost-
effectiveness ratio (ICER) will be calculated, i.e. the ratio
of the difference in costs between CBT and TAU/SH
divided by the difference in effects. Under statutory health
insurance perspective on cost, ICER will be calculated
using health sector costs only. Adopting the societal per-
Table 1: Endpoints, measurement instruments and time of data collection
Endpoint Questionnaire Time of measurement (Month)
Baseline M 3 M 6 M 9 M 12 M 15
Person-years free of moderate or severe major depression Depression module of the SCID xx x
QALYs EQ-5D
SF-36
x xxx x x
Health sector costs Cost questionnaire xx x x
Patient costs Cost questionnaire xx x x
Societal productivity/time costs Cost questionnaire xx x xBMC Geriatrics 2009, 9:25 http://www.biomedcentral.com/1471-2318/9/25
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spective, also patient costs and societal productivity/time
costs will be added to the calculation of the ICER.
Estimating effects
Calculation of depression-free years
Person-years free of moderate/severe major depression
will be calculated based on incidence of moderate or
severe major depression in different treatment groups.
Translation of HRQoL measures into QALYs
For the purposes of economic analysis, measures compa-
rable across disease areas are preferred. Most popular out-
come measure for this purpose are the quality adjusted
life-years (QALYs), which explicitly combine length and
quality of life in a single measure, weighting survival (a set
of health states) by utility scores. Utility weights reflect
preferences for a particular health state and are measured
on a scale from 0 to 1, where 0 and 1 represent death and
full health, respectively [23,24]. Although the MIND-DIA
study does not include a utility measurement as part of its
protocol, it does include SF-36 und EQ-5D questionnaires
measuring health related quality of life. Standardized
algorithms exist to translate EQ-5D and SF-36 scores into
utility weights suitable for calculation of QALYs [25,26].
The descriptive system of the EQ-5D allows for 243
unique health states. A preference-based scoring function
can be used to convert the descriptive information to a
summary index score (utility weight). More than 15 value
sets are available for scoring the EQ-5D, based on rating
scale and time trade-off (TTO) valuation derived from
general population surveys in various countries (includ-
ing the United Kingdom, Germany, and the United States)
[27]. In this study the scoring function derived from a sur-
vey of the general population in Germany will be used to
calculate utility weights from EQ-5D responses [28].
Brazier and colleagues reported work on deriving a
reduced health status index from the SF-36 that they
termed the SF-6D [29] and more recently, they have pub-
lished an algorithm that allows the estimation of utility
weights for all states of the SF-6D index [30]. Following
this published algorithm, SF-36 scores observed in the
trial will be converted to utility weights. Since the values
underlying this algorithm were obtained in the United
Kingdom, utilities derived from SF-36 scores will be only
used to perform a sensitivity analysis.
In the MIND-DIA study, the SF-36 and EQ-5D instru-
ments will be administered at baseline, after the interven-
tion (at 3 months), and then quarterly during a 1 year
follow-up (see Table 1), generating a maximum of six pos-
sible observations for each patient enrolled in the trial.
QALYs will be calculated assuming linear interpolation
between measurement points and calculating the area
under the curve to give a QALY score per patient over the
trial period [24].
Estimating costs: measurement and valuation of resource use
Measurement of resource use
Resource use directly associated with CBT and SH (e.g.
patients' and staff time due to screening and treatment)
will be derived from the therapy protocols. Information
on the other healthcare consumption will be obtained
from trial participants by means of a cost questionnaire,
which was developed for this purpose and incorporated
into the case report files of the MIND-DIA trial. The ques-
tionnaire will be administered before the intervention
(baseline), at 6, 12, and 15 months of the trial and refers
to the previous 6 or 3 (for the last assessment) months
(see Table 1). The cost form includes structured no/yes
questions on the utilization of different medical services
under the following categories: primary care visits, visits
to emergency departments, visits to specialists, hospital
stays, medication, and other therapies/paramedical care.
If patients indicate that they received specific medical care
over the past 6 or 3 months, they are asked to specify the
volume: e.g. number of contacts with healthcare provid-
ers, number and length of hospitalizations, types and dos-
age of obtained medications. In the cost questionnaire
patients are also asked to indicate whether health care
services obtained by them were paid by the health insur-
ance or self-paid, which makes an assessment of out-of-
pocket expenses possible.
Furthermore, (leisure) time losses will be measured by (i)
registering the number of 'disability' days (days of
reduced activity at home) with the cost questionnaire and
(ii) estimating average times of receiving medical care
from data on health services utilization in the trial groups.
Note that the majority of patients enrolled into the trial
are expected to be retirees. Hence, only (leisure) time
losses and not productivity losses (i.e. time missed from
work) are captured in the analysis.
Health sector costs
To estimate costs from the statutory health insurance
point of view, direct healthcare resource use of the inter-
ventions and other reported healthcare utilization (con-
sultations, hospital days, etc.) will be multiplied by unit
costs/prices. Currently, there are no German guidelines
for costing in economic evaluations containing standard
unit costs. Hence, healthcare resource use will be valued
by unit costs/prices obtained from published sources and
official statistics for Germany (e.g. charges and rates from
administrative databases, pharmacy retail prices).
Patient costs
To estimate patient costs, reported consumption of
healthcare services paid out of pocket will be multipliedBMC Geriatrics 2009, 9:25 http://www.biomedcentral.com/1471-2318/9/25
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by unit costs/prices available from official statistics and
from providers. Patient travel costs will be calculated
based on the amount of health care utilization and on
average distances to health care providers.
Societal productivity/time costs
Days of reduced activity at home and time of receiving
medical care will be valued using average net wage rates,
which represent opportunity costs of lost unpaid work
and leisure according to the human capital approach.
Statistical analysis of costs and effects
Mean total costs, health sector costs, patient costs and pro-
ductivity/time costs of interventions as well as corre-
sponding cost differences between the CBT group and
TAU/SH group will be calculated. Sampling uncertainty
will be estimated using bootstrap procedure because cost
data are non-normally distributed.
Incidence rates of moderate/severe major depression in all
groups will be estimated, along with 95% confidence
intervals. The incidence rate ratio (the incidence rate of
moderate or severe major depression in the CBT group
over the incidence rate in the TAU/SH group) will be ana-
lysed by regressing depression status at follow-up on the
type of intervention in a Poisson model.
Effect in terms of QALYs will be analysed using linear
regression on type of intervention and – if necessary – on
baseline utility score, which has been shown to be impor-
tant for the unbiased assessment of mean QALY differ-
ences between treatment groups [31].
Imputation of missing information on costs and effects
Data will be analysed according to the intention to treat
principle. A multiple imputation approach based on pro-
pensity scoring will be used to account for missing infor-
mation with regard to effects and costs. Baseline variables
(e.g. age, gender, cost at baseline, etc.) will be entered into
a logistic regression to predict the chance of a missing
value [32,33]. Available data will be arranged into quin-
tiles based on this predicted probability (propensity
score) and a replacement value for missing data will be
selected at random from the available data points within
the same quintile. By choosing a value at random within
the same quintile the principle of multiple imputations
could be employed, whereby each missing value is
replaced by m > 1 simulated values [34-36]. Each of m
resulting data sets will be analysed as described above and
combined to produce a single result that takes uncertainty
in the imputation process into account.
Determining cost-effectiveness
If a significant impact of CBT on both effects and costs is
demonstrated, ICER will be estimated in terms of costs per
year free of moderate/severe major depression and per
QALY gained. ICER will be estimated for the total cost
(health sector costs plus patient costs plus societal produc-
tivity costs) and for the health sector costs (statutory
health insurance perspective) separately. The non-para-
metric bootstrap method will be employed to generate
confidence intervals around the ICER estimates derived
from the study sample [37,38]. Uncertainty surrounding
the ICER will also be presented on the cost-effectiveness
plane [39,40] and as the cost-effectiveness acceptability
curve [41,42].
Sensitivity analyses
Besides statistical uncertainty (sampling variation) with
regard to costs and effects, every economic evaluation may
contain some degree of data imprecision (e.g. resource
costs/prices) and methodological controversy (e.g. deriva-
tion of utility weights, discount rate), which should be
accounted for. To handle this type of uncertainty, sensitiv-
ity analysis is usually employed [23,24,43]. In the sensi-
tivity analysis (uncertain) parameter(s) of the base-case
analysis are varied to determine if changes in these param-
eters influence the results. Univariate sensitivity analyses
will be performed by varying health service unit costs and
utility weights (see Table 2). Further, in order to assess
how a simultaneous change of several variables affects the
cost-effectiveness ratio, a multivariate sensitivity analysis
will be performed. To fully appreciate the potential influ-
ence of missing responses and of the imputation method
chosen, sensitivity analyses examining the effect of alter-
native imputation methods (linear extrapolation and
complete case analysis) will be conducted. When conduct-
ing sensitivity analysis, we will report both the revised
Table 2: Summary of planed sensitivity analyses
Parameter/methodological assumption Base-case Sensitivity analysis
Utility weights for QALYs derived from EQ-5D derived from SF-36
Unit costs/prices of resource use data from published sources and official statistics for 
Germany
varied within a plausible range
Imputation method multiple imputation linear extrapolation, complete case analysisBMC Geriatrics 2009, 9:25 http://www.biomedcentral.com/1471-2318/9/25
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point estimates and revised confidence intervals for costs,




Identification of resource use/attribution
Research has shown consistent association between
depression symptoms and increased total healthcare utili-
zation and costs in patients with diabetes, even after con-
trolling for co-morbidities. Consequently, it is difficult to
identify (and to measure) resource use related to depres-
sion. In the context of the trial, it might be argued that, if
true randomisation is achieved, any differences in cost
between treatment arms can be attributed to the study
intervention [44]. Hence, data on utilization of a broad
range of health services will be collected in the MIND-DIA
trial. On the one hand, this approach allows avoiding the
neglect of any unexpected changes in resource use related
to the interventions being compared. On the other hand,
however, it may complicate the detection of statistically
significant difference in health service costs, since the lat-
ter have been shown to be highly variable and therefore to
require larger overall sample sizes [44,45].
Measurement of resource use
Information on healthcare utilization other than CBT and
SH sessions will be collected by self-report by means of
the cost questionnaire. To our knowledge no standard and
validated instruments for collecting resource use data in
clinical trials are available in Germany. Hence, we devel-
oped a data collection instrument specifically for the
MIND-DIA trial. The questionnaire was pilot tested, but
has not yet been validated against other data sources.
Recall bias may potentially occur, since resource use will
be measured over the previous 6 or 3 months. However,
there is no conclusive evidence regarding whether a pro-
spective (a cost diary) or a retrospective (a questionnaire)
instrument should be better applied and regarding an
appropriate recall interval (44). Van den Brink et al. found
that for the assessment of healthcare utilization in eco-
nomic evaluations alongside clinical trials, a cost ques-
tionnaire may replace a cost diary for recall periods up to
6 months [46] and that such patients' self-reports are a
valid source of data on days of hospitalization and out-
patient visits, whereas costs of medication may be under-
estimated [47].
Time costs
In this study days of reduced activity at home and time of
receiving medical care will be monetary valued using aver-
age net wage rates representing opportunity cost of
unpaid work and leisure according to the human capital
approach. It is contentious, however, whether lost (lei-
sure) time should be measured in terms of costs or effects
[23,24,48,49]. In particular, lost (ability to enjoy) leisure
time might as well be reflected in QALYs, since health
related quality of life instruments, e.g. the EQ-5D and the
SF-36, explicitly ask about problems in performing leisure
activities and social activities [48]. Thus, double counting
may occur. We nevertheless decided to capture time costs
in the numerator of the cost-effectiveness ratio, when
adopting the societal perspective, because it is unclear to
what extent changes in (leisure) time are measured by
QALYs and the true societal loss may be underestimated
otherwise. Furthermore, this approach will help to avoid
some unpalatable equity implications, since time missed
from work due to treatment or illness is most often cap-
tured in monetary terms.
Conclusion
Depression and depression symptoms co-occurring with
type 2 diabetes are highly prevalent and associated with a
wide range of adverse outcomes, including less effective
self-care, more severe physical symptoms, greater func-
tional impairment and disability as well as increased
healthcare utilization and expenditure. However, there is
a lack of evidence on effectiveness of treatment options
for minor or mild-major depression co-occurring with
diabetes. Therefore, the MIND-DIA trial will evaluate the
effectiveness of cognitive behaviour therapy for treatment
of sub-threshold depression in elderly patients with type
2 diabetes, comparing it to a self-help group intervention
and to usual care.
The negative impact of co-morbid depression on both
health effects and total costs suggests that the more effec-
tive treatment of depression might not only improve
health outcomes in patients with diabetes, but also
change the pattern of health services use and therefore
total healthcare costs. Costs for depression treatment
might be balanced by reduction in other healthcare utili-
zation or even lead to savings in total costs. Thus, besides
testing the effectiveness of CBT as a treatment option to
improve quality of life and to avoid the onset of a moder-
ate or severe major depression in elderly patients with
type 2 diabetes and minor or mild-major depression, cost-
effectiveness of the CBT should be examined as well. The
economic evaluation conducted alongside the MIND-DIA
trial will provide additional evidence on whether CBT is a
cost-effective strategy in this target group. Importantly,
since patients are followed for 15 months, long-term
incremental costs and effects of the CBT will be captured.
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